Bromocriptine

證據等級: L5

預測適應症: 10 個

Bromocriptine: From Parkinson’s Disease / Hyperprolactinemia to Schizophrenia

One-Sentence Summary

Bromocriptine is a dopamine D2/D3 receptor agonist with long-established use in Parkinson’s disease, hyperprolactinemia, acromegaly, and type 2 diabetes (Cycloset formulation). The TxGNN model predicts potential therapeutic relevance in schizophrenia, with 3 clinical trials and 20 publications currently supporting this direction — though the mechanistic relationship is fundamentally paradoxical and requires careful patient stratification.

Quick Overview

Item	Content
Original Indication	Parkinson’s disease, hyperprolactinemia, acromegaly
Predicted New Indication	Schizophrenia
TxGNN Prediction Score	99.73%
Evidence Level	L3
India Market Status	✗ Not Marketed
Number of Registrations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Bromocriptine is an ergot-derived dopamine agonist with high affinity for D2 and D3 receptors, along with partial D1 agonist activity and serotonin 5-HT2C agonist properties. In Parkinson’s disease, its mechanism is straightforward: it directly stimulates post-synaptic D2 receptors to compensate for the loss of nigrostriatal dopamine neurons. This well-characterized dopaminergic pharmacology forms the basis for the TxGNN prediction in schizophrenia.

Schizophrenia involves a spatially heterogeneous dopamine dysregulation: mesolimbic hyperdopaminergia drives positive symptoms (delusions, hallucinations), while mesocortical hypodopaminergia in the prefrontal cortex underlies negative symptoms (blunted affect, avolition, cognitive impairment) and accounts for the substantial unmet need in treatment. Standard antipsychotic drugs are D2 antagonists that effectively control positive symptoms but do little — and may even worsen — the prefrontal dopamine deficit. Bromocriptine, acting as a D2 agonist, theoretically targets the negative symptom domain by correcting this prefrontal hypo-dopaminergic state, particularly when used as an adjunct under the “umbrella” of a D2 antagonist antipsychotic.

However, this mechanistic logic carries an inherent paradox: bromocriptine’s D2 agonist activity in the mesolimbic system could simultaneously exacerbate positive symptoms. Published case reports have documented bromocriptine-induced de novo psychosis in predisposed individuals. A second, more established clinical niche exists: bromocriptine as an adjunct to reverse antipsychotic-induced hyperprolactinemia, since chronic D2 blockade in the pituitary raises prolactin, causing sexual dysfunction, osteoporosis, and metabolic disturbances. These two potential roles — negative symptom augmentation vs. prolactin management — have different risk-benefit profiles and must be assessed separately.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT03575000	Phase 4	Not Yet Recruiting	15	Open-label adjunctive bromocriptine in schizophrenia patients with antipsychotic-induced prediabetes/insulin resistance; evaluates safety, tolerability, and metabolic benefit of bromocriptine as a Cycloset-class dopamine agonist added to existing antipsychotic regimens
NCT00315081	Phase 3	Unknown	20	Bromocriptine for risperidone-induced hyperprolactinemia in schizophrenic patients; endocrinological assessment with serial hormone measurement
NCT04181385	Phase 2/3	Unknown	15	Lipid and metabolic response to olanzapine in healthy adults; tests whether bromocriptine can counteract antipsychotic-induced metabolic disturbances (indirect relevance)

Literature Evidence

PMID	Year	Type	Journal	Key Findings
31688399	2019	Systematic Review	J Clin Psychopharmacology	Meta-analysis of prodopaminergic agents (including bromocriptine) as adjuncts for negative symptoms of schizophrenia; evaluates evidence for dopamine agonist strategy targeting prefrontal hypodopaminergia
18480682	2008	RCT	J Clin Psychopharmacology	Randomised crossover comparing herbal preparation (Peony-Glycyrrhiza Decoction) vs bromocriptine for risperidone-induced hyperprolactinemia in schizophrenia patients
2643996	1989	Pilot RCT	Biological Psychiatry	Low-dose bromocriptine (2.5 mg/day) adjunct to haloperidol vs placebo in 30 schizophrenic patients; acute 29% improvement in total BPRS score within 24 hours in the bromocriptine arm
8561400	1995	Clinical Study	Annales Médico-Psychologiques	12 schizophrenic patients on bromocriptine 7.5 mg/day + neuroleptic showed mean 29% improvement in total PANSS score at one month; supports adjunctive neuroleptic-bromocriptine combination
1679383	1991	Clinical Report/Pilot	Comprehensive Psychiatry	Open clinical exploration of bromocriptine combined with neuroleptics specifically for “negative schizophrenia”; theoretical basis in D2 agonism for prefrontal dopamine deficit
6574535	1983	Clinical Trial (small, uncontrolled)	Psychiatry Research	10 chronic schizophrenics treated with escalating bromocriptine (up to 40 mg/day); psychopathological assessment via BPRS and prolactin response to haloperidol challenge
26573387	2016	Case Report	Nordic J Psychiatry	Early-onset schizophrenia on paliperidone: adjunctive bromocriptine resolved hyperprolactinemia and tremors and — strikingly — also improved negative symptoms; supports dual benefit hypothesis
21157697	2011	Clinical Observational	Pharmacopsychiatry	Disorganized schizophrenia patients did not deteriorate when exposed to dopamine agonists (cabergoline/bromocriptine) used for ablactation; suggests subgroup safety under specific conditions
8120934	1993	Case Report	J National Medical Assn	New-onset schizophrenia in a 53-year-old man 4 days after starting low-dose bromocriptine for macroprolactinoma; fully resolved within 5 days of discontinuation — confirms psychosis risk and dopamine hypothesis
33571431	2021	Structural Biology	Cell	Cryo-EM structures of human D1R and D2R signalling complexes at atomic resolution; establishes mechanistic framework for dopaminergic drugs (including bromocriptine) in Parkinson’s disease, schizophrenia, and other neuropsychiatric disorders

India Market Information

Bromocriptine currently has no registered products in India (CDSCO database). No authorization numbers, brand names, or approved indications on record.

Note: Bromocriptine is approved in multiple other markets (FDA, EMA) for Parkinson’s disease, hyperprolactinemia, acromegaly, and type 2 diabetes. A regulatory pathway assessment would be needed before any India market application.

Safety Considerations

Drug Interactions (87 total identified via DDInter):

Major interactions (require avoidance or mandatory clinical supervision):

Isometheptene: Major — combined vasoconstrictive/sympathomimetic effects; risk of hypertensive crisis
Lorcaserin: Major — overlapping serotonergic and dopaminergic activity; serotonin syndrome risk

Clinically significant moderate interactions (selected):

Metoclopramide: Dopamine antagonist; directly opposes bromocriptine’s mechanism and reduces efficacy — combination should be avoided in psychiatric settings
Promethazine: Dopamine antagonism similarly reduces bromocriptine activity
Clarithromycin: CYP3A4 inhibitor; may significantly raise bromocriptine plasma levels and increase adverse effects
Ethanol: Enhanced CNS depression and hypotensive effects; advise abstinence
Morphine / Opium / Difenoxin / Diphenoxylate: Opioid co-administration enhances CNS/respiratory depression
Amyl Nitrite: Combined vasodilation may cause severe hypotension
Dronabinol / Nabilone: CNS depression potentiation
Ioflupane I-123 (DaTscan): Bromocriptine may interfere with dopamine transporter imaging; discontinue before neuroimaging

Conclusion and Next Steps

Decision: Hold

Rationale: The mechanistic basis for bromocriptine in schizophrenia is a double-edged sword — its D2 agonism could theoretically improve negative symptoms (prefrontal dopamine deficiency) but simultaneously carries a documented risk of exacerbating positive symptoms (mesolimbic hyperdopaminergia), which is directly contrary to the effect of standard-of-care antipsychotics. Current evidence is limited to small pilot trials, observational reports, and a systematic review (L3), with no completed large-scale Phase 3 RCT demonstrating net clinical benefit. The paradoxical mechanism, together with the documented case of bromocriptine-induced schizophrenia, means the risk-benefit ratio is unacceptably uncertain at this stage.

To proceed, the following is needed:

Resolve DG001 (Blocking): Obtain and parse official package insert (CDSCO equivalent / FDA/EMA label) for complete contraindications and black-box warnings — this is a mandatory prerequisite before any safety evaluation
Resolve DG002 (High): Retrieve full DrugBank mechanism of action data for bromocriptine to formally document receptor binding profile, pharmacodynamics, and pharmacokinetics
Establish a regulatory pathway assessment for India, given zero current CDSCO registrations
Clearly define the clinical use case before any trial design: (a) adjunctive treatment for antipsychotic-induced hyperprolactinemia (lower risk, precedent exists) vs (b) adjunctive treatment for negative symptoms (higher risk, requires Phase 2 RCT with strict inclusion criteria)
For the negative symptom indication: require stable positive symptom control, mandatory concomitant antipsychotic coverage, and consider biomarker stratification (prefrontal dopamine availability, D2 receptor occupancy imaging) to identify responder subgroups
Conduct a formal pharmacovigilance review of psychosis adverse events reported with bromocriptine use in published literature before any clinical development proceeds
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.